FRK
ENSG00000111816
Target class
Kinase
Chromosome
6
Approved drugs
2
Clinical candidates (approved and in development)
6
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- FRK
- Gene name
- Fyn related Src family tyrosine kinase
- Gene symbol
- FRK
- Previous gene symbols
- PTK5
- Protein name
- Tyrosine-protein kinase FRK (EC 2.7.10.2) (FYN-related kinase) (Nuclear tyrosine protein kinase RAK) (Protein-tyrosine kinase 5)
- RAK
- GTK
- Gene biotype
- Protein coding
- Gene family
- SH2 domain containing|Src family tyrosine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 28
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 8.67
- Tissue specificity (Gini)
- 0.544
- Tissue specificity (tau)
- 0.817
- KEGG gene identifiers
- hsa:2444
- Protein interaction confidence
- 0.896333
- Protein interaction partners
- 6
- R-HSA-6798695
- R-HSA-8948751
- End position
- 116061093
- Start position
- 115931149
- Chromosome
- 6
- Strand
- Reverse
- Cytoplasm . Nucleus . Note=Predominantly found in the nucleus, with a small fraction found in the cell periphery.
- Cytosol
- Nucleoplasm
Publication evidence
- PubMed 7696183
- Tissue specificity (tau)
- 0.816805
- Expression inequality (Gini)
- 0.543958
Expression in transcripts per million
- Artery - Tibial
- 8.67
- Artery - Coronary
- 7.54
- Artery - Aorta
- 7.33
- Minor Salivary Gland
- 4.84
- Esophagus - Mucosa
- 4.67
Expression in transcripts per million
- Artery - Tibial8.67
- Artery - Coronary7.54
- Artery - Aorta7.33
- Minor Salivary Gland4.84
- Esophagus - Mucosa4.67
- Kidney - Medulla4.24
- Kidney - Cortex3.98
- Stomach3.79
- Liver3.11
- Small Intestine - Terminal Ileum3.1
- Colon - Transverse2.9
- Cells - EBV-transformed lymphocytes2.82
- Vagina2.16
- Testis2.12
- Lung2.05
- Cervix - Ectocervix2.01
- Prostate1.78
- Pancreas1.73
- Bladder1.6
- Cervix - Endocervix1.47
- Fallopian Tube1.37
- Heart - Left Ventricle1.31
- Adrenal Gland1.31
- Breast - Mammary Tissue1.29
- Brain - Spinal cord (cervical c-1)1.25
And 29 more, listed on the interactive page.
Biological processes
- GO:0000122
- GO:0005576
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0005829
- GO:0035578
- GO:0035580
- GO:0070062
- GO:0004713
- GO:0004715
- GO:0005515
Related records
Trials (407)
- "Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
- [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
- [18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial
- [18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma
- [68 Ga]-DOTANOC PET/CT in GEP-NETs
- [68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas
- [68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation
- 11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET)
- 18F-DCFBC PET/CT in Prostate Cancer
- 18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
- 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
- 68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis
- 68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.
- 68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC
- 68Ga-PSMA PET/CT in Prostate Cancer
- 68Ga-PSMA PET/CT in Prostate Cancer
- 68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Intermediate Risk Prostate Cancer Imaging
- 68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Prostate Cancer Imaging According to Various Metastatic Risks
- 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
Drugs (6)
- Dasatinib anhydrous SRC inhibitor
- ENMD-981693 SRC inhibitor
- Ilorasertib SRC inhibitor
- Regorafenib Tyrosine-protein kinase FRK inhibitor
- TG100-801 SRC inhibitor
- XL-228 SRC inhibitor